Company profile

Hangzhou Sumgen Biotech Co., Ltd.

Privately held: no public share price (Chinese antibody-therapeutics biotech (oncology/autoimmune), ~$71M raised across Series A/A+ (Dealroom/Crunchbase). No public listing found; private. Sources: https://clinicaltrials.gov/study/NCT04684108 ; https://api.gleif.org/api/v1/lei-records/984500G84CRC0D4B3920 ; https://api.gleif.org/api/v1/lei-records/984500CE07P48BCA4D79 ; https://api.gleif.org/api/v1/lei-records/254900IPMS6ZUSN90C79 ; https://api.gleif.org/api/v1/lei-records/254900KZ4D0BVC9CPW92 ; https://api.gleif.org/api/v1/lei-records/894500TSKNE8XM67HY36 Entity resolved by asset-pipeline-v2.)